spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  epinephrine 

 HSMN NewsFeed - 27 Mar 2026
Otsuka Pharmaceutical to Acquire Transcend Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 9 Aug 2024
FDA Approves First Nasal Spray for Treatment of Anaphylaxis
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 28 Mar 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 9 Feb 2022
ARS Pharmaceuticals Expands Executive Leadership Team with Addition of Pharmaceutical Commercialization Veterans
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2021
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2020
REYVOW(R) (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Sep 2020
REYVOW(TM) (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 9 Sep 2020
Phosplatin Therapeutics Announces Two Leadership Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Nov 2019
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Nov 2018
Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Aug 2018
Janssen Announces Results from MARINER and COMMANDER HF Studies
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Aug 2018
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 26 Jun 2018
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA(TM) (lofexidine)
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 May 2018
Egalet Announces Large Regional Plan to Cover SPRIX(R) Nasal Spray
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 2 Mar 2018
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2018
Grifols HyperRAB(R) (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Dec 2017
Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2017
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Nov 2017
U.S. FDA Approves Kaléo's AUVI-Q(R) (Epinephrine Injection, USP) 0.1 mg Auto-Injector for Life-Threatening Allergic Reactions in Infants and Small Children
Biopharmaceuticals Devices Drug Delivery FDA
 HSMN NewsFeed - 30 Oct 2017
FDA Approves New 10 mg Dosing for XARELTO(R) (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Aug 2017
Mylan Finalizes Settlement Agreement on Medicaid Rebate Classification for EpiPen(R) Auto-Injector
Biopharmaceuticals Drug Delivery Litigation Reimbursement
 HSMN NewsFeed - 7 Aug 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba(TM) in Germany, France and Austria
Biopharmaceuticals Distribution
 HSMN NewsFeed - 27 Jul 2017
U.S. FDA Grants Priority Review for an Epinephrine Auto-Injector in Development by Kaléo Specifically for Infants and Small Children
Biopharmaceuticals Devices Drug Delivery FDA
 HSMN NewsFeed - 25 Jul 2017
HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 21 Jul 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jul 2017
Fagron, Inc. Announces Launch Of LETS GEL KIT(TM) for Rapid Topical Anesthesia
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 2 May 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba(R) (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries
Biopharmaceuticals Distribution
 HSMN NewsFeed - 3 Mar 2017
Otsuka Pharmaceutical to Acquire Neurovance, Inc.
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 5 Jan 2017
Eisai Acquires All Global Development And Marketing Rights For Chronic Weight Management Treatment Lorcaserin HCI
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 27 Dec 2016
Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene(R) Mist
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Nov 2016
Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution
 HSMN NewsFeed - 31 Oct 2016
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2016
Neurocrine Announces INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Aug 2016
Mylan Taking Immediate Action to Further Enhance Access to EpiPen(R) (Epinephrine Injection, USP) Auto-Injector
Biopharmaceuticals Devices Drug Delivery Reimbursement
 HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Biopharmaceuticals Acquisitions Product Launch
 HSMN NewsFeed - 14 Jun 2016
Nephron Pharmaceuticals Corporation Launches Generic Budesonide Inhalation Suspension
Biopharmaceuticals Generics Drug Delivery Product Launch
 HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 6 Jun 2016
Allergan Announces FDA Approval of BYVALSON(TM) (nebivolol and valsartan)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 29 Mar 2016
Adamis Pharmaceuticals Announces Agreement to Acquire US Compounding
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Mar 2016
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE(R) in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 2 Feb 2016
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Jan 2016
Antares Pharma Announces CEO Transition
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Dec 2015
Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2015
Antares Pharma Announces FDA Approval of Sumatriptan Injection USP
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Aug 2015
S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Aug 2015
Timothy E. Morris Joins PAION Inc. As A Non Executive Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2015
Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Nov 2014
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2014
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Aug 2014
Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 May 2014
FDA Approves ZONTIVITY(TM) (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 30 Jan 2014
Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Jan 2014
Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director
Biopharmaceuticals Neurology Cardiology Personnel
 HSMN NewsFeed - 15 Jan 2014
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 19 Nov 2013
Antares Pharma Appoints David H. Bergstrom Ph.D. as Senior Vice President Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Nov 2013
Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease Portfolio; Will Augment Already Strong Growth Prospects
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Jun 2013
Eisai Announces Availability of BELVIQ(R) (lorcaserin HCl) CIV Tablets for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2013
Six Month Data Reported for WAVE I Study of Renal Denervation Therapy for Hypertension at EuroPCR Meeting in Paris
Devices Cardiology
 HSMN NewsFeed - 23 Apr 2013
FDA Approves Second Drug in BD Simplist(TM) Prefilled Injectable Line of Products
Biopharmaceuticals Devices Drug Delivery Generics FDA
 HSMN NewsFeed - 27 Mar 2013
BD Enters Pharmaceutical Industry with New Line of Generic Prefilled Injectable Products
Biopharmaceuticals Generics Drug Delivery FDA
 HSMN NewsFeed - 22 Mar 2013
FDA Approves GE Healthcare's AdreView(TM) (Iobenguane I 123 Injection) for Cardiac Risk Evaluation in Heart Failure Patients
Biopharmaceuticals Cardiology Radiology FDA
 HSMN NewsFeed - 13 Nov 2012
Antares Pharma Announces Positive Results from Final MTX Medi-Jet(TM) Clinical Study
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 13 Aug 2012
Sanofi Announces FDA Approval for Auvi-Q(TM), First Voice-guided Epinephrine Auto-injector for Patients with Life-threatening Allergies
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Mar 2012
AstraZeneca and Targacept Announce Remaining TC-5214 Phase 3 Efficacy Studies Do Not Meet Primary Endpoint, Regulatory Filing Will Not Be Pursued
Biopharmaceuticals
 HSMN NewsFeed - 26 Aug 2011
NUCYNTA(R) ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jan 2011
Zogenix and Desitin Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Dec 2010
Mylan's Dey Pharma Partners with Meda to Market EpiPen(R) Auto-Injector in Europe
Biopharmaceuticals Drug Delivery Distribution
 HSMN NewsFeed - 22 Nov 2010
Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta(R) Delayed-Release 20, 30 and 60 mg Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 4 Nov 2010
Euthymics Bioscience, Inc. Names Biotech Executive Timothy J. Barberich to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 30 Oct 2010
Forest Announces FDA Approval of Teflaro(TM) (ceftaroline fosamil) for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Oct 2010
FDA Issues Complete Response Letter to Johnson & Johnson Pharmaceutical Research & Development Regarding New Drug Application for Tapentadol Extended Release
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jul 2010
Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Feb 2010
Adamis Pharmaceuticals Signs Agreement to Acquire Prostate Cancer Drug Candidates
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 23 Feb 2010
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 16 Feb 2010
La Jolla Pharmaceutical Company Calls Urgent Special Meeting of Stockholders on February 26, 2010 to Vote on Merger
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Feb 2010
Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2009
Adamis Pharmaceuticals Announces Signing of Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Dec 2009
La Jolla Pharmaceutical Company Announces Signing of Definitive Merger Agreement With Adamis Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Dec 2009
New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Nov 2009
sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
Devices Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Nov 2009
ARCA Receives FDA Fast Track Designation for Gencaro(TM) Development in Genotype-Defined Heart Failure Population
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 22 Oct 2009
Zogenix and Astellas Announce Data Published Showing the Benefits of SUMAVEL(TM) DosePro(TM) Needle-Free Delivery System
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 12 Oct 2009
CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Sep 2009
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
Biopharmaceuticals
 HSMN NewsFeed - 3 Aug 2009
Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Biopharmaceuticals
 HSMN NewsFeed - 20 Jul 2009
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX(R) (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jul 2009
Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2009
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2009
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
Biopharmaceuticals
 HSMN NewsFeed - 7 Apr 2009
Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
Biopharmaceuticals
 HSMN NewsFeed - 31 Mar 2009
GE Healthcare Announces Data from Phase III Study of AdreView in Heart Failure Patients
Biopharmaceuticals Cardiology Radiology
 HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jan 2009
Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2008
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2008
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2008
Impax Sued Based on Anda for Generic Cymbalta(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Aug 2008
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals
 HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Aug 2008
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2008
William D. Schwieterman, M.D. Joins Chelsea Therapeutics' Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jun 2008
FDA Approves Cymbalta(R) for the Management of Fibromyalgia
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2008
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Biopharmaceuticals
 HSMN NewsFeed - 28 May 2008
XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2008
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2008
FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2008
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Apr 2008
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2008
Presidio Pharmaceuticals Obtains Exclusive Worldwide Rights to XTL Biopharmaceuticals Ltd. Hepatitis C Virus (HCV) NS5A Program
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Mar 2008
XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Mar 2008
Sciele Pharma Acquires Twinject(R) Epinephrine Auto-Injector from Verus Pharmaceuticals
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 25 Feb 2008
Cypress Bioscience to Acquire Proprius Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Feb 2008
Two New Independent Directors Join Chelsea Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2008
Chelsea Therapeutics Begins Patient Dosing in Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension
Biopharmaceuticals
 HSMN NewsFeed - 31 Dec 2007
Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Dec 2007
Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2007
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 30 Nov 2007
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Nov 2007
FDA Accepts Chelsea Therapeutics' Investigational New Drug Application for Droxidopa
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Oct 2007
Xytis Names Gordon H. Busenbark as Chief Financial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Oct 2007
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2007
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Oct 2007
Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 15 Oct 2007
FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 2 Oct 2007
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Sep 2007
Paladin and Labopharm Launch Tridural(TM) Once-Daily Tramadol Product in Canada
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
Biopharmaceuticals
 HSMN NewsFeed - 14 Aug 2007
European Commission Grants Chelsea Therapeutics Two Orphan Medicinal Product Designations for Droxidopa
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Biopharmaceuticals
 HSMN NewsFeed - 24 Jul 2007
Wyeth Receives Approvable Letter from FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated with Menopause
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2007
Study Suggests Strattera(R) Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2007
Molecular Insight Pharmaceuticals, Inc. Initiates Azedra(TM) Therapeutic Trial in Neuroendocrine Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2007
Advanced Magnetics Announces Positive Results from Two Additional Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapeutic
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2007
BROVANA(TM) Inhalation Solution Now Available by Prescription for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2007
Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 26 Feb 2007
FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jan 2007
Wyeth Receives Approvable Letter From FDA for Pristiq (Desvenlafaxine Succinate) for the Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2007
XTL Biopharmaceuticals Announces the In-Licensing of Bicifadine - A Late-Stage Clinical Compound for the Treatment of Neuropathic Pain
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
XOPENEX HFA(R) Data Presented at American College of Allergy, Asthma and Immunology Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2006
Study Suggests Strattera(R) Was Effective in Treating ADHD in Children and Adolescents With ADHD and Reading Disorders
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2006
Study Suggests Strattera(R) was Effective in Treating ADHD in Children and Adolescents with ADHD and Reading Disorders
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2006
Data for XOPENEX(R) Brand of Levalbuterol Presented at American College of Chest Physicians Annual Conference
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2006
OREXIGEN(TM) Therapeutics Reports Positive Phase II Results for Excalia(TM) Combination-Therapy to Treat Obesity
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2006
DOV Pharmaceutical, Inc. Announces New Strategic Direction, Bicifadine Clinical Studies Results and Program Updates
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2006
Halozyme and Baxter Announce Availability of Hylenex for Subcutaneous Delivery of Medications and Fluids
Biopharmaceuticals
 HSMN NewsFeed - 25 May 2006
Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement in Symptoms of Depression in Adult Patients Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2006
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 106

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 106 additional stories matching:
epinephrine
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!